In FY13, Piramal Enterprises sold its domestic pharmaceutical formulations business to Abbott Laboratories for ₹17,000 crore and had invested part of the proceeds in Shriram Group companies. Piramal invested ₹4,583 crore across three Shriram Group entities, according to a Crisil report.

Leave a Reply

Your email address will not be published. Required fields are marked *

Generated by Feedzy